Analysis of fluoxetine and norfluoxetine in human plasma by liquid-phase microextraction and injection port derivatization GC–MS

Oliveira, Antônio Felipe Felicioni; Figueiredo, Eduardo Costa; Santos-Neto, Álvaro José

doi:10.1016/j.jpba.2012.04.006

Cited by 45 publications

(24 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The techniques perform high sensitivity and provide well separation. However, majority specimens are subjected to different preparation methods prior to analysis [20][21][22][23][24]. It is usually time consuming and labor intensive.…”

Section: Introductionmentioning

confidence: 99%

Rapid label-free determination of ketamine in whole blood using secondary ion mass spectrometry

Liao

Chen

Shyue

et al. 2015

Talanta

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Rapid label-free determination of ketamine in whole blood using secondary ion mass spectrometry

Liao

Chen

Shyue

et al. 2015

Talanta

View full text Add to dashboard Cite

“…The drug, marketed as fluoxetine hydrochloride, has a recommended daily dosage ranging from 20 to 80 mg day −1 , and its therapeutic effect can be observed after 2–3 weeks of initiation of treatment. In general, the maximum plasma concentrations occur within 6–8 h after drug intake, typically ranging from 30 to 500 ng mL −1 (Baumann, ; Oliveira, Figueiredo, & Santos‐Neto, ). Therapeutic drug monitoring (TDM) applies quantitation in serum or plasma for dose optimization, which is given by the sum of the drug concentration with its active metabolites that also contribute to the overall clinical effect.…”

Section: Introductionmentioning

confidence: 99%

Optimization and validation of an SBSE–HPLC–FD method using laboratory‐made stir bars for fluoxetine determination in human plasma

Marques

Nakahara

Madeira

et al. 2018

Biomedical Chromatography

View full text Add to dashboard Cite

Depression is the largest cause of disability worldwide, affecting 350 million people.Notwithstanding that clinical trials demonstrate antidepressants efficacy, the efficient response can vary individually concerning therapeutic dosage. Although important, plasma levels monitoring remains an analytical challenge whereas clean-up and preconcentration represent critical steps. Therefore, this study aims to develop, optimize and validate a method for fluoxetine determination in human plasma, employing a laboratory-made device consisting of a PDMS stir bar sorptive for extraction, coupled with high-performance liquid chromatography-fluorescence detection (SBSE-HPLC-FD). Optimization involved sorption-desorption steps. For sorption, temperature and time were assessed by factorial and central composite design approaches, taking into account the desirability and the response surface results, with stirring speed also examined. For desorption kinetics and ultrasonic and magnetic stirring mode were evaluated. The proposed method after validation was robust, linear (25.00-1000.00 ng mL −1 , R 2 > 0.98) and presented good intra-(RSD 4.18%) andinter-day-assay (RSD 11.60%) precision and accuracy (recovery 109.60%), allowing reliable quantitation without interference. The method was successfully applied to real samples. SBSE-HPLC-FD could represent a feasible alternative with good cost-benefit for low-volume samples and therapeutic drug monitoring, as well as contributing to correlation studies between plasma fluoxetine levels and clinical response, which is still little studied.

show abstract

“…Therefore, developing a very sensitive analytical method for the determination of FLX is of great importance (4). Several methods have been reported for the quantitation of FLX in various samples including capillary electrophoresis (5), nuclear magnetic resonance spectrometry (6), chromatography (7)(8)(9), chromatography-mass spectrometry (4,10,11), electrochemical methods (12,13), spectrophotometry (14)(15)(16) and spectrofluorimetry (2,17,18). Many of these methods have some major drawbacks such as lack of selectivity, tedious extraction procedures and time-consuming procedures.…”

Section: Introductionmentioning

confidence: 99%

Determination of fluoxetine in pharmaceutical and biological samples based on the silver nanoparticle enhanced fluorescence of fluoxetine–terbium complex

Lotfi

Manzoori

2016

Luminescence

View full text Add to dashboard Cite

In this study, a simple and sensitive spectrofluorimetric method is presented for the determination of fluoxetine based on the enhancing effect of silver nanoparticles (AgNPs) on the terbium-fluoxetine fluorescence emission. The AgNPs were prepared by a simple reduction method and characterized by UV-Vis spectroscopy and transmission electron microscopy. It was indicated that these AgNPs have a remarkable amplifying effect on the terbium-sensitized fluorescence of fluoxetine. The effects of various parameters such as AgNP and Tb concentration and the pH of the media were investigated. Under obtained optimal conditions, the fluorescence intensity of the terbium-fluoxetine-AgNP system was enhanced linearly by increasing the concentration of fluoxetine in the range of 0.008 to 19 mg/L. The limit of detection (b + 3s) was 8.3 × 10 mg/L. The interference effects of common species found in real samples were also studied. The method had good linearity, recovery, reproducibility and sensitivity, and was satisfactorily applied for the determination of fluoxetine in tablet formulations, human urine and plasma samples. Copyright © 2016 John Wiley & Sons, Ltd.

show abstract

Analysis of fluoxetine and norfluoxetine in human plasma by liquid-phase microextraction and injection port derivatization GC–MS

Cited by 45 publications

References 44 publications

Rapid label-free determination of ketamine in whole blood using secondary ion mass spectrometry

Rapid label-free determination of ketamine in whole blood using secondary ion mass spectrometry

Optimization and validation of an SBSE–HPLC–FD method using laboratory‐made stir bars for fluoxetine determination in human plasma

Determination of fluoxetine in pharmaceutical and biological samples based on the silver nanoparticle enhanced fluorescence of fluoxetine–terbium complex

Contact Info

Product

Resources

About